Speaker(s):
Presentation: Funds from the Federal 21st Century Cures Act were distributed to all states by SAMHSA in Spring, 2017 and will continue through Spring, 2019, to address the opioid crisis in the form of State Targeted Response to the Opioid Crisis (STR) grants. This talk will review the landscape of opioid use and overdose deaths in Missouri and how the Opioid STR grant efforts have aimed to curb the trend of increasing death rates and change the system of care in our state. Though the goals of STR span initiatives in the realms of prevention, treatment, and recovery support, this talk will focus mostly on treatment. Specifically, the treatment of opioid use disorder through Missouri’s STR “Medication First” treatment model, which prioritizes timely access to stabilizing medications, reduced barriers to medication across diverse treatment settings, and the availability of medication maintenance treatment for as long as a person benefits from it. This talk will also provide an early summary of findings from the first year of STR treatment implementation and highlight current and upcoming opioid-related updates, including a review of the new implanted and injectable formulations of buprenorphine.
Objectives:
- Identify the most promising medical and harm reduction practices being used around the world to decrease opioid-related morbidity and mortality, including an introduction to new formulations of buprenorphine products (implants and injections) for maintenance treatment
- Identify the key role the “Medication First” treatment model plays in managing Opioid Use Disorder
- Describe the recent Missouri trends in opioid overdose and treatment utilization, including early findings from Missouri’s State Targeted Response grant efforts
Slides and Handouts: